Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725675 | 1.00 | PTPN1 (0.51) | PTPN1MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL2307401 | 1.00 | PTPN1 (0.51) | PTPN1MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL12059890 | 0.92 | MDM4 (0.51) | PTPN1CASP3MDM2MDM4TP53 | |
| SCHEMBL31097650 | 0.92 | MDM4 (0.51) | PTPN1CASP3MDM2MDM4TP53 | |
| SCHEMBL31097655 | 0.91 | HDAC8 (0.49) | PTPN1MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL12052763 | 0.89 | MDM2 (0.54) | PTPN1KMT2ACASP3MDM2MDM4 | |
| SCHEMBL8106707 | 0.89 | MDM2 (0.54) | PTPN1KMT2ACASP3MDM2MDM4 | |
| SCHEMBL12531899 | 0.88 | ATM (0.53) | ALDH1A1LMNAGAACASP3MDM4 | |
| SCHEMBL2977877 | 0.88 | ATM (0.53) | ALDH1A1LMNAGAACASP3MDM4 | |
| SCHEMBL13743302 | 0.88 | ATM (0.53) | ALDH1A1LMNAGAACASP3MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | PTPN1 3855/4885MEN1 1631/4885ALDH1A1 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.